A new paper proposed a mechanism linking spermidine, one of the most popular longevity supplements, to cancer cell proliferation, and the group flagged it immediately.
The pattern is familiar: a compelling mechanism and promising observational data, followed by a trial or mechanistic study that complicates the picture. Antioxidant vitamins looked strong early before large trials came back neutral or harmful. Metformin followed a similar arc for cancer prevention.
The honest position for now: spermidine's longevity benefits may be real, but we do not know whether the same pathways that promote autophagy could also accelerate tumor growth in susceptible people.
Key takeaways
- Treat spermidine as unproven in patients with cancer history or high cancer risk.
- Mechanistic promise is not outcome evidence.
From Buzz in the chat, the longevitydocs™ Sunday newsletter, March 22, 2026. Member discussion, not clinical guidance.
Originally published in The Longevity Medicine Intelligence newsletter.
